CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $109.3 million in its second quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.67. Losses, adjusted for non-recurring costs and stock option expense, were 43 cents per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.
The biopharmaceutical company posted revenue of $73.5 million in the period, also surpassing Street forecasts. Nine analysts surveyed by Zacks expected $70.9 million.
Sarepta Therapeutics shares have more than doubled since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $121.02, more than tripling in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT